FORMULATION AND DEVELOPMENT OF FIXED-DOSE COMBINATION OF BI-LAYER TABLETS OF EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS 600 MG/300 MG/300 MG

JONNA SANKARAIAH; NEERAJ SHARMA; MOHD. JAVED NAIM

doi:10.22159/ijap.2022v14i1.42764

Authors

JONNA SANKARAIAH Department of Pharmaceutics, Bhagwant University, Ajmer, Rajasthan, India
NEERAJ SHARMA Faculty of Pharmacy, Bhagwant University, Ajmer, Rajasthan, India
MOHD. JAVED NAIM Faculty of Pharmacy, Bhagwant University, Ajmer, Rajasthan, India

DOI:

https://doi.org/10.22159/ijap.2022v14i1.42764

Keywords:

Fixed-dose formulation, Human immunodeficiency virus (HIV1) infection, Bilayer compression, Efavirenz, Lamivudine, and tenofovir

Abstract

Objective: This study is to formulate bi-layer tablet as a multidrug regimen against each reference listed drugs of Brand SUSTIVA® (efavirenz tablets 600 mg), EPIVER®(lamivudine tablets 300 mg), and VIREAD®(tenofovir disoproxil tablets 300 mg) to treat human immunodeficiency virus (HIV) infections. Which provides highly active antiretroviral therapy to provide effective treatment.

Methods: Bilayer formulation was developed with each blend of layer-I (efavirenz) and layer-II (lamivudine and tenofovir disoproxil fumarate) through wet granulation process and roller compaction process, respectively. Further, both layers were compressed by using bi-layer compression followed by film coating. Layer-I and II formulations were developed by using various concentrations of diluents, surfactants, and disintegrants to improve the solubility of efavirenz and improve the flowability and uniformity of layer-II. Finally, the optimum formulation was developed to compare the in vitro dissolution with each branded formulation.

Results: Drug-excipients interaction results revealed that the mixtures of three drug substances in 50 °C/75 % relative humidity (RH) resulted in an increase in tenofovir IMP-E and the highest unknown impurity was significantly increased and additionally decreased tenofovir assay in the presence of efavirenz. Sodium lauryl sulfate is very critical and it acts as a wetting agent and increases the solubility of efavirenz, and directly influences the dissolution of a drug product. Microcrystalline and croscarmellose sodium have a chance to affect the dissolution and friability of tenofovir. Powdered cellulose was acting as a diluent and flow property of the lamivudine part and it also affects the uniformity and dissolution. So, these ranges were optimized. X-ray diffraction (XRD) indicates there are no polymorphic changes for the optimized formulation and there is no interaction between the three active substances, and finally, in vitro dissolution results for the optimized formulation against the reference drugs.

Conclusion: Optimum formulation yielded consistent drug release against each branded drug to treat human immunodeficiency virus (HIV1) infections. This formulation is robust and easily scale up for the next stage.

Downloads

Download data is not yet available.

References

Collier R. Reducing the pill burden. CMAJ. 2012;184(2):E117-8. doi: 10.1503/cmaj.109-4076, PMCID 3273525. PMID 22231682.

Joseph D, Thomas GM. A review on current applications of bilayer tablets. Res J Pharm Technol. 2019;12(5):2539-44. doi: 10.5958/0974-360X.2019.00427.X.

Devi KV, Pai RS. Antiretroviral: need for an effective drug delivery. Ind JP Sci. 2006. p. 1-6.

Witvrouw M, Van Maele B, Vercammen J, Hantson A, Engelborghs Y, De Clercq E, Pannecouque C, Debyser Z. Novel inhibitors of HIV-1 integration. Curr Drug Metab. 2004 Aug;5(4):291-304. doi: 10.2174/1389200043335487, PMID 15320701.

Chaudhary KPR, Devi A. International GS. J Res Pharm Sci. Manuscript No. IJRPC-254.

Flexner C. Antiretroviral agents and treatment of HIV infection. In: Brunton L, Chabner B, editors, Knollmann B. Goodman and Gilman's pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. p. 1623-64.

Martin A. Micromeretics. In: Martin à physical pharmacy. Baltimores. Lippincott Williams & Wilkins; 2001. p. 423-54.

Tibalinda P, Pius D, Shedafa R, Masota N, Temu M, Kaale E. Pre-formulation development of lamivudine 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg fixed dose combination tablets. PP. 2016;07(7):247-54. doi: 10.4236/pp.2016.77031.

Srilatha U, Ramakrishna M, Vasavi reddy D, Srinivas Reddy Devireddy. Formulation and evaluation of Emitricitabine and tenofovir disoproxil fumarate film coated tablets. Int J Res Pharm Sci. 2015:116-25.

Thota S, Radhalakshmi AK, Krishnanrajan D, Parthiban KG. Formulation and evaluation of immediate release tablets of lamivudine, zidovudine and nevirapine. Asian J Pharm Clin Res. 2009:54-61.

Panikumar AD, Venkatraju Y, Sunitha G, Sathesh babu PR, Subrahmanyam CVS et al. Development of biorelavent and discriminating method for dissolution of efavirenz and its formulations. Asian J Pharm Clin Res. 2012;5(3):220-3.

International Conference of Harmonization (ICH). Harmonized Tripartide guidelines for stability testing of new drug substances and products Q1A Convention, Inc. Vol. R2. Rockville, MD: United States Pharmacopoeial; 2003. p. 6.

Roy M, Ahmed I, Aziz I, Manju Pandy. Formulation and evaluation of efavirenz 600 mg tablet. Mohd. Yaqub khan. Asian J Res Pharm Sci. 2015:153-67.

Prosper Tibalinda J Sempombe, Raphael Shedafa. Formulation development and optimization of lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg FDC tablets by D-optimal mixture design; 2016. p. e00207. doi: 10.1016/j.heliyon,december2016,e00207.

https://extranet.who.int/pqweb/sites/default/files/HA593part4v1.pdf [Last accessed on 10 Dec 2021]

https://www.medicines.org.uk/emc/product/9129/smpc#gref. [Last accessed on 10 Dec 2021]

https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. [Last accessed on 10 Dec 2021]

Handbook of pharmaceutical excipients Sheskey PJ, Hancock BC, Moss Gp, Goldfarb DJ, editors. 9th ed. 2020.

Cristoforetti R, Anita Nair, Bertil Abrahamsson. Biowaiver monographs for immediate release solid oral dosage forms: efavirenz. J Pharm Sci. 2013. doi: 10.1002/jps.23380.